KAIYUAN SECURITIES·2025-05-21 14:42Group 1: Electric Power Equipment and New Energy - In Q1 2025, European BEV sales from companies like Renault, Volkswagen, and BMW saw significant growth, with Renault's BEV sales up by 88%, Volkswagen's by 113%, and BMW's by 64% [5][6] - Chinese automakers are increasing exports to Europe, with BYD's sales reaching 14,000 units, a 124% year-on-year increase, while MG's sales dropped by 47% [6] - European automakers are set to launch new electric vehicle models from 2025 to 2026, which is expected to solidify the trend towards electrification [7] - The pressure from carbon emission assessments is high, but the introduction of new models is anticipated to help exceed targets by 2027 [8] Group 2: Social Services - Recent research highlights hyaluronic acid (HA) as a key factor in the aging process, marking a shift towards systemic interventions in anti-aging strategies [10][11] - Huaxi Biological Technology has positioned itself at the forefront of ECM research, with two new anti-aging products recently approved, indicating a shift from local to systemic interventions in anti-aging [12][13] Group 3: Media - Bilibili reported a revenue of 7.003 billion yuan in Q1 2025, a 23.6% year-on-year increase, with a net profit of 362 million yuan, indicating a turnaround from losses [15][16] - The platform's DAU reached 107 million, a 4.5% increase year-on-year, with MAU hitting a record high of 368 million, suggesting strong user growth [17][19] - The company is expected to benefit from the growth in gaming, membership, advertising, and IP monetization, driving future revenue growth [15][19] Group 4: Pharmaceuticals - The company has increased its stake in AR882 to 100%, enhancing its market position for this gout treatment, which shows significant potential for growth [21][22] - AR882 has demonstrated superior efficacy and safety in clinical trials, positioning it as a best-in-class product in the market [22][23] - The company is increasing its R&D investment, with a pipeline of 15 innovative drugs showing promising early-stage results [23]